News and insights
223 81 Lund, Sverige
+46 46-15 21 00
©Copyright 2022 CLS AB. All rights reserved.
Using Minimally Invasive Laser Ablation
The challenges in healthcare are many. At CLS we are committed to developing better therapies for use in cancer care and neurosurgery. We do this by providing tools for precise tissue ablation using heat generated by laser light. Our close collaboration with healthcare professionals ensures our products meet their requirements and seamlessly fits into hospital workflows. This enables more patients to be treated based on their specific diagnosis and needs. Carefully precise.
February 15, 2023
Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally – without damaging healthy tissue. The procedure is minimally invasive and thus gentle on the patient, who typically can return quickly to normal life.
A tumor or epileptogenic foci in the brain means major challenges – for the patient and for healthcare. When using laser ablation in neurosurgery the lesion is directly targeted and treated with high precision. The treatment spares healthy tissue and causes less side effects than surgery and chemotherapy.
The thermal effects on cells depend mainly on two factors – temperature and time. Research has shown that moderate heating of cancerous tumor cells during a long time will not only kill the targeted tumor itself, but also activate the immune system to attack cancer cells throughout the body.
Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed CLS TRANBERG® Thermal Therapy Systems – seamlessly integrated systems for laser ablation, with several options for real time monitoring and control of the treatment.
We are proud to release a detailed video animation of the minimally invasive, fusion-guided, focal laser ablation (FLA) of a prostate tumor using the TRANBERG™ Thermal Therapy System.
We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.
Listen to an interview with one of the patients treated in the ongoing CLS-sponsored study at Skåne University Hospital, in Lund, Sweden.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region